Maze Therapeutics Inc. (MAZE)
Market Closed
3 Sep, 20:00
NASDAQ (NMS) NASDAQ (NMS) Primary $
25. 87
-0.85
-3.1811%
$
1.52B Market Cap
- P/E Ratio
- Div Yield
477,427 Volume
- Eps
$ 26.72
Previous Close 
Want to track MAZE and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Maze Therapeutics targets up to $728 mln valuation in US IPO
Drug developer Maze Therapeutics said on Monday it was targeting a valuation of as much as $728.1 million in its initial public offering in the United States.
Reuters | 1 year ago
Maze Therapeutics Seeks IPO For Trials Ramp-Up
Maze Therapeutics aims to raise $100 million in an IPO to fund clinical trials for its kidney and related disease treatments. The company's lead candidate, MZE829, is in Phase 2 trials for APOL1 kidney disease, with promising Phase 1 results. Maze has strong financial backing and a significant partnership with Shionogi & Co., positioning it well for future development.
Seekingalpha | 1 year ago
